William Blair Issues Negative Forecast for Zoetis Earnings

Zoetis Inc. (NYSE:ZTS) – Investment analysts at William Blair lowered their Q1 2025 earnings estimates for Zoetis in a research note issued on Thursday, February 13th. William Blair analyst B. Vazquez now forecasts that the company will post earnings per share of $1.37 for the quarter, down from their prior estimate of $1.38. The consensus estimate for Zoetis’ current full-year earnings is $5.90 per share. William Blair also issued estimates for Zoetis’ Q1 2025 earnings at $1.37 EPS, Q2 2025 earnings at $1.59 EPS, Q2 2025 earnings at $1.59 EPS, Q3 2025 earnings at $1.62 EPS, Q3 2025 earnings at $1.62 EPS, Q4 2025 earnings at $1.47 EPS, Q4 2025 earnings at $1.47 EPS, FY2025 earnings at $6.05 EPS, Q1 2026 earnings at $1.52 EPS, Q1 2026 earnings at $1.52 EPS, Q2 2026 earnings at $1.74 EPS, Q2 2026 earnings at $1.74 EPS, Q3 2026 earnings at $1.76 EPS, Q3 2026 earnings at $1.76 EPS, Q4 2026 earnings at $1.62 EPS, Q4 2026 earnings at $1.62 EPS, FY2026 earnings at $6.64 EPS and FY2026 earnings at $6.64 EPS.

A number of other equities analysts have also weighed in on ZTS. Stifel Nicolaus decreased their price target on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Leerink Partners started coverage on shares of Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 target price on the stock. Piper Sandler reduced their target price on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a report on Monday, February 10th. UBS Group started coverage on shares of Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 target price on the stock. Finally, Morgan Stanley reduced their target price on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $214.90.

Zoetis Stock Down 0.7 %

ZTS stock opened at $156.43 on Monday. The stock has a market capitalization of $70.58 billion, a P/E ratio of 29.40, a PEG ratio of 2.77 and a beta of 0.90. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. Zoetis has a one year low of $144.80 and a one year high of $200.53. The company has a 50 day moving average price of $168.10 and a two-hundred day moving average price of $178.61.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The business had revenue of $2.32 billion during the quarter, compared to analysts’ expectations of $2.30 billion.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.28%. The ex-dividend date is Monday, April 21st. Zoetis’s dividend payout ratio is presently 37.59%.

Insider Activity at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the sale, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at $2,757,196.26. This represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.16% of the company’s stock.

Institutional Investors Weigh In On Zoetis

A number of large investors have recently made changes to their positions in ZTS. Atlantic Edge Private Wealth Management LLC raised its holdings in shares of Zoetis by 482.8% during the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after acquiring an additional 140 shares during the period. Rakuten Securities Inc. raised its holdings in shares of Zoetis by 5,533.3% during the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock valued at $28,000 after acquiring an additional 166 shares during the period. Navigoe LLC acquired a new stake in shares of Zoetis during the fourth quarter valued at approximately $30,000. Darwin Wealth Management LLC acquired a new stake in shares of Zoetis during the third quarter valued at approximately $31,000. Finally, First Personal Financial Services acquired a new stake in shares of Zoetis during the third quarter valued at approximately $33,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.